Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

NCT05107427 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor unable to proceed

Conditions

Urothelial Carcinoma

Interventions

DRUG: MRx0518
BIOLOGICAL: Avelumab 20 mg/mL Intravenous Solution (IV)

Sponsor

4D pharma plc